VRDN Live signals | Maximize Profits with Getagraph.com

BUY 93941 min ago

@ $18.37

Issued: 14 Feb 2024 @ 14:55

Return: -20.52%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 1.83 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	1.47M
Average Volume	905 672
Market Cap	916.41M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $-1.070 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.75
ATR14	$0.0190 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Fairmount Funds Management Llc	Buy	5 859	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	21 999	Series A Non-Voting Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	5 859	Common Stock
2024-03-28	Fairmount Funds Management Llc	Sell	21 999	Series A Non-Voting Convertible Preferred Stock
2024-02-12	Tousignant Jennifer	Buy	0

INSIDER POWER
58.74
Last 95 transactions
Buy: 5 352 885 \| Sell: 1 550 540

Volume Correlation

Long: -0.06 (neutral)

Short: -0.49 (neutral)

Signal:(50.628) Neutral

Viridian Therapeutics, Correlation

10 Most Positive Correlations
TBNK	0.946
RGLD	0.946
MCHI	0.941
ISEM	0.939
HCM	0.938
IMVT	0.938
QFIN	0.935
PGJ	0.933
WLFC	0.932
ROIV	0.924

10 Most Negative Correlations
LLNW	-0.934
PCRX	-0.918
SFET	-0.915
SWAV	-0.913
ASPS	-0.913
GRIN	-0.907
NKTX	-0.906
RTPY	-0.895
LAWS	-0.893
LNSR	-0.889

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Viridian Therapeutics, Correlation - Currency/Commodity

0.08
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.31
( neutral )

-0.44
( neutral )

-0.63
( weak negative )

Viridian Therapeutics, Financials

Annual	2023
Revenue:	$314 000
Gross Profit:	$-1.01M (-321.02 %)
EPS:	$-5.31

Q4	2023
Revenue:	$72 000.00
Gross Profit:	$-278 000 (-386.11 %)
EPS:	$-1.350

Q3	2023
Revenue:	$72 000.00
Gross Profit:	$-263 000 (-365.28 %)
EPS:	$-1.090

Q2	2023
Revenue:	$72 000.00
Gross Profit:	$-360 000 (-500.00 %)
EPS:	$-1.270

Financial Reports:

No articles found.

Viridian Therapeutics,

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.